

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 08 March 2022.

I am pleased to confirm the following.

I am investigating the use of targeted therapies in blood-related cancers. Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma? Further, how many have received the following treatments?

Total Number of patients treated: 79

Treatment	Patients in last 3 months
Bortezomib [Velcade] and Dexamethasone	11
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	6
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	7
Lenalidomide [Revlimid] monotherapy	16
Lenalidomide [Revlimid] and Dexamethasone	10
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone	0
Lenalidomide [Revlimid], Melphalan and Prednisolone	0
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]	0
Bortezomib [Velcade] monotherapy	0
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]	1
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]	1
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	0
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone	0
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)	0
Daratumumab [Darzalex] monotherapy	13
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	0

Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]	0
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]	7
Pomalidomide [Imnovid] and Dexamethasone	2
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone	0
Any other systemic anti-cancer treatment	5

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

<p>Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.</p>
